Gene therapy tried in dogs with muscle disease could prove useful for people

Dog with arthritis
The University of Washington led a study of gene therapy in dogs with a muscle disorder that also affects people.

There’s a rare disorder that occurs when a gene mutation halts the production of myotubularin—a protein that facilitates normal muscle function. The disease, called myotubular myopathy (MTM), only affects males, and it’s ultimately fatal because it causes breathing difficulties.

Dogs get MTM, too—and that spelled opportunity for scientists at the University of Washington Medicine Institute for Stem Cell and Regenerative Medicine. In collaboration with five other academic institutions, they found a way to replace the faulty MTM gene with a functioning gene in dogs with the disease, they reported in the journal Molecular Therapy.

It worked: After a single infusion of genes, muscle strength was restored in the dogs, according to a press release. One year later, the dogs were indistinguishable from healthy animals, they said. "This regenerative technology allowed dogs that otherwise would have perished to complete restoration of normal health," said Dr. Martin K. "Casey" Childers, UW Medicine researcher and physician.

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

The researchers used a viral vector called adeno-associated virus serotype 8 (rAAV8) to deliver a healthy canine version of the MTM gene in dogs that were 10 weeks old and already showing symptoms. They believe a similar trial could be designed in people.

Gene therapy is under investigation for a wide range of disorders, though much of the progress to date has occurred outside the realm of muscular disorders. BioMarin Pharmaceutical, for example, is in mid-stage trials of a gene therapy treatment for hemophilia A. UniQure is working on several gene therapy products to treat diseases including Huntington’s and congestive heart failure. Its most advanced project, a gene therapy product to treat hemophilia B, received breakthrough designation status from the FDA in January.

One company that has achieved some success with gene therapy in inherited muscle disorders is AveXis, which is gearing up for a pivotal trial of its treatment for spinal muscular atrophy. AveXis won breakthrough therapy designation for its gene product last year, and high hopes for the product have prompted its stock to more than triple since the company went public early last year.

UW Medicine-led team that worked on the canine MTM trial observed that as they increased the dosage of genes, survival rates improved, they reported. They believe the study proves the potential utility of gene therapy in a wide range of diseases that are linked to mutated genes.

Suggested Articles

Spinal Elements, maker of a wide range of implants and products for minimally invasive spine procedures, has filed a $100 million IPO.

United Airlines will begin providing COVID-19 screening tests for passengers, allowing those who test negative to skip local quarantine requirements.

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.